Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

33.88 -0.04 (-0.10%)
Streaming Delayed Price Updated: 2:14 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report ↗
Amid the election, and a Fed rate vote, earnings season roars ahead. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today ↗
 
Via Benzinga
News headline image
A Closer Look at 4 Analyst Recommendations For Teva Pharmaceutical Indus ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug ↗
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes ↗
Teva Pharmaceuticals will pay $450 million to resolve allegations of kickback schemes involving Medicare copays and price-fixing. This settlement is part of a broader crackdown on healthcare fraud... 
Via Benzinga
Topics Fraud
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today ↗
 
Via Benzinga
News headline image
Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected ↗
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga
News headline image
Teva Launches Generic Version Of Sandostatin In The US ↗
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down Tuesday. Here's what you need to know. 
Via Benzinga
News headline image
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast ↗
Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the... 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today ↗
 
Via Benzinga
News headline image
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars ↗
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
News headline image
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies ↗
Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated to education, recovery centers, and outreach initiatives. 
Via Benzinga
News headline image
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
News headline image
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
News headline image
Organon Stock Sees Relative Strength Rating Rise To 91 ↗
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
Via Investor's Business Daily
News headline image
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets ↗
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,... 
Via Benzinga
News headline image
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold ↗
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. 
Via Investor's Business Daily
News headline image
$100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
The 7 Best Under $20 Stocks to Buy in August 2024 ↗
Although cheap stocks are often cheap for a reason, it doesn't hold true for the best stocks under $20, which is where investors can profit. 
Via InvestorPlace
News headline image
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks. ↗
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours. 
Via InvestorPlace
News headline image
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday? ↗
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting. 
Via Benzinga
Topics Economy
News headline image
Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Teva Pharmaceutical Industries (TEVA) Q2 2024 Earnings Call Transcript ↗
TEVA earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Teva Beats Q2 Estimates, Raises Annual Outlook On Strong Generic, Austedo Sales ↗
Teva Pharmaceutical reported Q2 2024 sales of $4.16 billion, surpassing the $4.06 billion consensus. Revenue rose 7% YoY, driven by growth in generic products and Austedo sales. Adjusted EPS was $0.61,... 
Via Benzinga
News headline image
Teva Pharma Flirts With Breakout As Generic Drugs Drive Beat-And-Raise ↗
The company now expects $16 billion to $16.4 billion in full-year sales. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility ↗
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD) 
Via Benzinga
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.